STOCK TITAN

Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Syndax Pharmaceuticals will report its Q3 2023 financial results and provide a business update on November 2. A conference call and webcast will be held to discuss the results.
Positive
  • Syndax Pharmaceuticals will provide a business update, which could positively affect the stock price.
Negative
  • None.

WALTHAM, Mass., Oct. 26, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2023 financial results and provide a business update on Thursday, November 2, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, November 2, 2023, to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: SNDX3Q23
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX3Q23.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com 
Tel 781.684.9827

SNDX-G

Cision View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-third-quarter-2023-financial-results-and-host-conference-call-and-webcast-on-november-2-2023-301967633.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals report its Q3 2023 financial results?

Syndax Pharmaceuticals will report its Q3 2023 financial results on November 2.

How can I access the conference call and webcast?

The conference call and webcast can be accessed through the Events & Presentations page on Syndax Pharmaceuticals' website.

Will there be a replay of the conference call and webcast?

Yes, a replay will be available on Syndax Pharmaceuticals' website for 90 days following the call.

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

SNDX Rankings

SNDX Latest News

SNDX Stock Data

1.42B
81.86M
0.81%
106.64%
12.5%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM